AngioDynamics (ANGO) reported Q4 2025 revenue of $80.16 million, surpassing estimates of $74.26 million by 8% and increasing 12.9% from $70.98 million a year ago.
The company posted an adjusted loss of $0.03 per share, beating the estimated loss of $0.12 and improving from a loss of $0.06 per share in the same quarter last year. For FY 2026, AngioDynamics expects earnings to range from a loss of $0.35 to $0.25 per share, wider than the estimated loss of $0.23.
Revenue is projected between $305.00 million and $310.00 million, slightly above the estimate of $304.86 million.
Earnings Insight
| Date | Time | Symbol | company_name | Period | Metric | Estimate | Actual | Surprise | YrAgo | Growth | sector_industry |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 07/15/2025 | BMO | ANGO | AngioDynamics | Q4 2025 | EPS | -0.12 | -0.03 | 75.00 | -0.06 | 50.00 | Healthcare / Medical Instruments & Supplies |
| 04/02/2025 | BMO | ANGO | AngioDynamics | Q3 2025 | EPS | -0.13 | -0.08 | 38.46 | Healthcare / Medical Instruments & Supplies | ||
| 01/08/2025 | BMO | ANGO | AngioDynamics | Q2 2025 | EPS | -0.13 | -0.04 | 69.23 | -0.05 | 20.00 | Healthcare / Medical Instruments & Supplies |
| 10/03/2024 | BMO | ANGO | AngioDynamics | Q1 2025 | EPS | -0.15 | -0.11 | 26.67 | -0.12 | 8.30 | Healthcare / Medical Instruments & Supplies |
| 07/16/2024 | BMO | ANGO | AngioDynamics | Q4 2024 | EPS | -0.16 | -0.06 | 62.50 | 0.02 | Healthcare / Medical Instruments & Supplies |